Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rheumatic Diseases | 3 | 2021 | 2675 | 0.83 | Why? |
| B-Cell Activating Factor | 1 | 2017 | 36 | 0.67 | Why? |
| Podocytes | 1 | 2017 | 82 | 0.67 | Why? |
| Arthritis | 1 | 2021 | 288 | 0.65 | Why? |
| Interleukin-4 | 1 | 2017 | 367 | 0.61 | Why? |
| Proteinuria | 1 | 2017 | 474 | 0.53 | Why? |
| Hydroxychloroquine | 8 | 2021 | 12447 | 0.51 | Why? |
| Interleukin-17 | 1 | 2017 | 602 | 0.46 | Why? |
| Extracellular Traps | 1 | 2021 | 1036 | 0.46 | Why? |
| Mass Media | 1 | 2020 | 837 | 0.44 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2020 | 1380 | 0.39 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.37 | Why? |
| Autoimmune Diseases | 1 | 2021 | 1996 | 0.33 | Why? |
| Chloroquine | 2 | 2020 | 3152 | 0.30 | Why? |
| Rheumatologists | 2 | 2020 | 346 | 0.29 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.27 | Why? |
| Janus Kinases | 2 | 2017 | 414 | 0.26 | Why? |
| Biomedical Research | 2 | 2020 | 5270 | 0.25 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.24 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.21 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.20 | Why? |
| Rituximab | 2 | 2017 | 1096 | 0.19 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2017 | 3 | 0.18 | Why? |
| Interleukin-6 | 1 | 2017 | 7522 | 0.18 | Why? |
| STAT6 Transcription Factor | 1 | 2017 | 28 | 0.18 | Why? |
| Janus Kinase 3 | 1 | 2017 | 46 | 0.18 | Why? |
| Therapies, Investigational | 1 | 2020 | 235 | 0.18 | Why? |
| Cyclic S-Oxides | 1 | 2017 | 3 | 0.18 | Why? |
| Cardiotoxicity | 1 | 2021 | 365 | 0.17 | Why? |
| Isoquinolines | 1 | 2017 | 69 | 0.16 | Why? |
| Interinstitutional Relations | 1 | 2018 | 170 | 0.16 | Why? |
| Interleukin-13 | 1 | 2017 | 204 | 0.16 | Why? |
| STAT Transcription Factors | 1 | 2017 | 173 | 0.16 | Why? |
| Kidney Glomerulus | 1 | 2017 | 144 | 0.15 | Why? |
| Protein-Tyrosine Kinases | 1 | 2017 | 158 | 0.15 | Why? |
| Antigen-Antibody Complex | 1 | 2017 | 408 | 0.15 | Why? |
| Antirheumatic Agents | 2 | 2020 | 3023 | 0.15 | Why? |
| Nephrotic Syndrome | 1 | 2017 | 146 | 0.15 | Why? |
| Adenine | 1 | 2017 | 463 | 0.13 | Why? |
| Mentors | 1 | 2018 | 372 | 0.13 | Why? |
| HeLa Cells | 1 | 2017 | 1303 | 0.13 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.13 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.12 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.12 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.12 | Why? |
| Recombinant Fusion Proteins | 1 | 2017 | 919 | 0.11 | Why? |
| Antibodies, Monoclonal | 3 | 2021 | 8041 | 0.11 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.10 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.10 | Why? |
| Pyrazoles | 2 | 2020 | 1791 | 0.10 | Why? |
| Public Opinion | 1 | 2020 | 1165 | 0.10 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.09 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.09 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.09 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.08 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.08 | Why? |
| Coronavirus Infections | 7 | 2021 | 253789 | 0.08 | Why? |
| Drug Approval | 1 | 2017 | 1325 | 0.08 | Why? |
| Rheumatology | 1 | 2018 | 1213 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.08 | Why? |
| Humans | 17 | 2021 | 930598 | 0.07 | Why? |
| Immunologic Factors | 2 | 2020 | 4206 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.07 | Why? |
| Education, Medical, Graduate | 1 | 2018 | 2082 | 0.06 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.06 | Why? |
| Mice | 2 | 2021 | 21357 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.05 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.04 | Why? |
| Bias | 1 | 2020 | 1109 | 0.04 | Why? |
| Purines | 1 | 2020 | 816 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.03 | Why? |
| Animals | 2 | 2021 | 78931 | 0.03 | Why? |
| Sulfonamides | 1 | 2020 | 1294 | 0.03 | Why? |
| Program Development | 1 | 2018 | 1089 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Cooperative Behavior | 1 | 2018 | 1216 | 0.02 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Communication | 1 | 2020 | 5206 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Female | 2 | 2020 | 380317 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Aged | 1 | 2020 | 215776 | 0.00 | Why? |
| Adult | 1 | 2020 | 244371 | 0.00 | Why? |
| Middle Aged | 1 | 2020 | 270681 | 0.00 | Why? |
| Male | 1 | 2020 | 367725 | 0.00 | Why? |
Kim's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(114)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(120)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_